The Framingham Heart Study is an icon of epidemiology. Its long-term monitoring of a large group, or cohort, of people in a Massachusetts town has yielded landmark results on everything from the link between cholesterol and heart disease to the genetic risk of stroke. But this year, the thorough clinical exams that participants periodically receive will be scaled back, and plans for new tests put on hold.
